Louisiana State Employees Retirement System Makes New $2.25 Million Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Louisiana State Employees Retirement System acquired a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 112,700 shares of the biotechnology company's stock, valued at approximately $2,253,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its stake in ADMA Biologics by 2.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock valued at $69,454,000 after acquiring an additional 92,281 shares during the last quarter. LSV Asset Management purchased a new position in shares of ADMA Biologics during the 1st quarter worth approximately $1,028,000. Seven Eight Capital LP purchased a new position in shares of ADMA Biologics during the 2nd quarter worth approximately $1,992,000. BNP Paribas Financial Markets raised its stake in shares of ADMA Biologics by 152.2% during the 1st quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company's stock worth $4,837,000 after buying an additional 442,315 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of ADMA Biologics during the 2nd quarter worth approximately $1,157,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the sale, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the sale, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ADMA. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of ADMA Biologics in a research note on Monday, October 14th. Cantor Fitzgerald reissued an "overweight" rating and set a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, ADMA Biologics presently has a consensus rating of "Buy" and a consensus target price of $15.50.

ADMA Biologics Price Performance

Shares of ADMA traded up $0.25 on Wednesday, reaching $16.96. The stock had a trading volume of 2,332,906 shares, compared to its average volume of 3,599,511. The firm has a market capitalization of $3.93 billion, a PE ratio of -843.00 and a beta of 0.62. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The firm has a 50-day moving average of $17.87 and a 200 day moving average of $13.22. ADMA Biologics, Inc. has a twelve month low of $3.23 and a twelve month high of $21.13.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to analysts' expectations of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company's revenue was up 78.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.02) EPS. Sell-side analysts expect that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.